Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1Eric Olinger, Olivier Devuyst, Constantinos Deltas et al.|Kidney International|2020Cited by 152
Hydrochlorothiazide and Prevention of Kidney-Stone RecurrenceNasser A. Dhayat, Daniel G. Fuster, Olivier Bonny et al.|New England Journal of Medicine|2023Cited by 128
Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trialNasser A. Dhayat, Daniel G. Fuster, Nicolas Faller et al.|BMC Nephrology|2018Cited by 33
Hydrochlorothiazide and Bone Mineral Density in Patients with Kidney StonesAndreas Christe, Daniel G. Fuster, Elias Primetis et al.|Clinical Journal of the American Society of Nephrology|2025Cited by 1